VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Brammer on Updates in the Treatment Landscape for T-Cell Lymphoma

Jonathan E. Brammer, MD
Published: Monday, Oct 30, 2017



Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses updates in the treatment landscape of T-cell lymphoma.

T-cell lymphoma has been an area of limited progress and poor prognosis, according to Brammer. An exciting development is with brentuximab vedotin (Adcetris), which is now being utilized for patients with relapsed CD30-positive anaplastic large-cell lymphoma. Some of those patients have long-term durable remissions.

For patients with cutaneous T-cell lymphoma, brentuximab vedotin is also highly effective, adds Brammer.
 


Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses updates in the treatment landscape of T-cell lymphoma.

T-cell lymphoma has been an area of limited progress and poor prognosis, according to Brammer. An exciting development is with brentuximab vedotin (Adcetris), which is now being utilized for patients with relapsed CD30-positive anaplastic large-cell lymphoma. Some of those patients have long-term durable remissions.

For patients with cutaneous T-cell lymphoma, brentuximab vedotin is also highly effective, adds Brammer.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x